736 results on '"Machin, S. J."'
Search Results
2. Lupus Anticoagulant Measurement
3. Metabolism of coversin, a complement C5 inhibitor with applications in haematological diseases: 124
4. Heparin-induced thrombocytopenia following plasma exchange in patients with demyelinating neurological disease
5. Disorders of Haemostasis
6. Mechanisms of Haemostasis
7. Recommendations For Patients Undertaking Self Management Of Oral Anticoagulation
8. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
9. ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features
10. The Productivity Effects of Unionization and Firm Size in British Engineering Firms
11. ICSH guidelines for the evaluation of blood cell analysers including those used for differential leucocyte and reticulocyte counting
12. Fifty years of the ICSH: 1964 to 2014
13. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome
14. The automation of routine light transmission platelet aggregation
15. Changes in the Antibody Status of a Population following Epidemic Infection by Influenza Virus A2/Hong Kong/1/68
16. Abc Of Clinical Haematology: Platelet Disorders
17. Increased resistance to recombinant human activated protein C and to activation of endogenous protein C in thrombotic antiphospholipid syndrome: 16
18. Coversin, a small protein complement inhibitor, is a potential novel anti-thrombotic agent: 5
19. Determination of APTT factor sensitivity - the misguiding guideline
20. Automation of light transmission platelet aggregation: PO 326
21. Thrombin generation testing to monitor warfarin anticoagulation in thrombotic antiphospholipid syndrome patients: PB 4.50–5
22. RAPS: a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE: PB 3.62–2
23. Mutations and polymorphisms in adult onset pregnancy related TTP: PB 2.33–2
24. The influence of anti-tissue factor pathway inhibitor (TFPI) antibodies on thrombin generation (TG) in thrombotic patients with and without antiphospholipid syndrome: PB 1.62–4
25. In vitro characterisation of two ADAMTS13 mutants (I143T, Y570C) identified in two patients with congenital thrombotic thrombocytopenic purpura (TTP): PA 4.19–6
26. Investigation of resistance to exogenous activated protein C and activation of endogenous protein C in thrombotic patients with or without antiphospholipid syndrome: PA 1.18–6
27. Role of complement in acute TTP: 28
28. Benefit of early administration of rituximab in acute TTP and prophylactic use to prevent relapse: 30
29. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
30. A comparative evaluation of a new automated assay for von Willebrand factor activity
31. A phenotype–genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom
32. Performance evaluation of the Celltac F haematology analyser
33. B cell-activating factor (BAFF) is elevated in acute idiopathic thrombotic thrombocytopenic purpura (TTP): 17
34. Development and application of a new automated thrombin generation assay that is sensitive to activated protein C resistance: 6
35. Evaluation of an automated platelet-based assay of ristocetin cofactor activity
36. Factor XIII – an under diagnosed deficiency – are we using the right assays?
37. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables
38. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura
39. Thrombotic thrombocytopenic purpura associated with statin therapy: 30
40. A comparison of rivaroxaban and fragmin prophylaxis after high risk orthopaedic surgery on thrombin generation test: 25
41. Anti-ADAMTS13 IgG antibody subclasses in thrombotic thrombocytopenic purpura and changes with rituximab therapy: 10
42. Acquired factor XIII deficiency - an under investigated disorder: 2
43. ADAMTS-13 assays in thrombotic thrombocytopenic purpura
44. Mean platelet volume: a quick, easy determinant of thrombotic risk?
45. The pharmacokinetics of rituximab in acute idiopathic thrombotic thrombocytopenic purpura (AITTP): OC-MO-138
46. Berend Houwen Memorial Lecture: ISLH Las Vegas May 2009
47. Quality counts: new parameters in blood cell counting
48. Serum rituximab levels in TTP: the effect of plasma exchange and correlation with response to treatment: 11
49. Persistent high factor VIII activity leading to increased thrombin generation: 8
50. Can automated blood film analysis replace the manual differential? An evaluation of the CellaVision DM96 automated image analysis system
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.